[1] World Health Organization. Listeriosis. 2018. Available from: https://www.afro.who.int/health-topics/listeriosis.
[2] World Health Organization. Disease outbreak - Listeriosis - South Africa - 28 March 2018. 2018. Available from: https://www.afro.who.int/health-topics/listeriosis/outbreak/28-march-2018-south-africa.
[3] Centers for Disease Control and Prevention. National Listeria Surveillance. 2018. Available from: https://www.cdc.gov/nationalsurveillance/listeria-surveillance.html.
[4] EFSA Panel on Biological Hazards, Ricci A, Allende A, Bolton D, Chemaly M, Davies R, et al. Listeria monocytogenes contamination of ready-to-eat foods and the risk for human health in the EU. EFSA Journal 2018;16(1):5134. Available from: http://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2018.5134.
[5] Carvalho F, Sousa S, Cabanes D. How Listeria monocytogenes organizes its surface for virulence. Front Cell Infect Microbiol,2014,4:48. doi: 10.3389/fcimb.2014.00048.
[6] Lorber B. Listeriosis. Clin Infect Dis. 1997,24(1):1-9; quiz 10-1. doi: 10.1093/clinids/24.1.1.
[7] Winslow DL, Damme J, Dieckman E. Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin. Antimicrob Agents Chemother,1983,23(4):555-8. doi: 10.1128/aac.23.4.555.
[8] Fernández Guerrero ML, Torres R, Mancebo B, González-López JJ, Górgolas M, Jusdado JJ, Roblas RF. Antimicrobial treatment of invasive non-perinatal human listeriosis and the impact of the underlying disease on prognosis. Clin Microbiol Infect,2012,18(7):690-5. doi: 10.1111/j.1469-0691.2011.03616.x.
[9] Manfredi R, Sabbatani S, Marinacci G, Salizzoni E, Chiodo F. Listeria monocytogenes meningitis and multiple brain abscesses in an immunocompetent host. Favorable response to combination linezolid-meropenem treatment. J Chemother,2006,18(3):331-3. doi: 10.1179/joc.2006.18.3.331.
[10] Cherubin CE, Appleman MD, Heseltine PN, Khayr W, Stratton CW. Epidemiological spectrum and current treatment of listeriosis. Rev Infect Dis,1991,13(6):1108-14. doi: 10.1093/clinids/13.6.1108.
[11] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 24th informational supplement. 2014. Available at: http://www.clsi.org/. Accessed January 2014.
[12] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6, 2016. http://www.eucast.org/. Accessed December 2016.
[13] Urban M, Cuzick A, Rutherford K, Irvine A, Pedro H, Pant R, Sadanadan V, Khamari L, Billal S, Mohanty S, Hammond-Kosack KE. PHI-base: a new interface and further additions for the multi-species pathogen-host interactions database. Nucleic Acids Res,2017,45(D1):D604-D610. doi: 10.1093/nar/gkw1089.
[14] Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res,2005,33(Database issue):D325-8. doi: 10.1093/nar/gki008.
[15] Liu B, Pop M. ARDB--Antibiotic Resistance Genes Database. Nucleic Acids Res,2009 37(Database issue):D443-7. doi: 10.1093/nar/gkn656.
[16] Clinical and Laboratory Standards Institute. Methods for Determining Bactericidal Activity of Antimicrobial Agents. 1999. Available at: http://www.clsi.org/. Accessed September 1999
[17] Blassmann U, Roehr AC, Frey OR, Vetter-Kerkhoff C, Thon N, Hope W, Briegel J, Huge V. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care,2016,20(1):343. doi: 10.1186/s13054-016-1523-y.
[18] Yu W, Shen P, Bao Z, Zhou K, Zheng B, Ji J, Guo L, Huang C, Xiao Y. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents,2017,50(2):237-241. doi: 10.1016/j.ijantimicag.2017.03.011.
[19] Luque S, Grau S, Alvarez-Lerma F, Ferrández O, Campillo N, Horcajada JP, Basas M, Lipman J, Roberts JA. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents,2014,44(5):409-15. doi: 10.1016/j.ijantimicag.2014.07.001.
[20] Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol,1989,46(11):1190-4. doi: 10.1001/archneur.1989.00520470044025.
[21] Shokouhi S, Alavi Darazam I. Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. J Infect. 2014,69(5):424-9. doi: 10.1016/j.jinf.2014.06.010.
[22] Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, Nightingale CH. Pharmacokinetics of Trimethoprim and Sulfamethoxazole in Serum and Cerebrospinal Fluid of Adult Patients with Normal Meninges. Antimicrob Agents Chemother,1984,26(6):811-4. doi: 10.1128/aac.26.6.811.
[23] Farber JM, Peterkin PI. Listeria monocytogenes, a food-borne pathogen. Microbiol Rev,1991,55(3):476-511.
[24] Chen SY, Lee JJ, Chien CC, Tsai WC, Lu CH, Chang WN, Lien CY. High incidence of severe neurological manifestations and high mortality rate for adult Listeria monocytogenes meningitis in Taiwan. J Clin Neurosci,2019, pii: S0967-5868(19)31244-5. doi: 10.1016/j.jocn.2019.08.072.
[25] Spanjaard L, Vandenbroucke-Grauls CM. Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid. Antimicrob Agents Chemother,2008,52(5):1850-1. doi: 10.1128/AAC.01139-07.
[26] Moreno LZ, Paixão R, Gobbi DD, Raimundo DC, Ferreira TP, Moreno AM, Hofer E, Reis CM, Matté GR, Matté MH. Characterization of antibiotic resistance in Listeria spp. isolated from slaughterhouse environments, pork and human infections. J Infect Dev Ctries,2014,8(4):416-23. doi: 10.3855/jidc.4188.
[27] Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother,2011,55(7):3345-56. doi: 10.1128/AAC.00207-11.
[28] Yang SJ, Mishra NN, Rubio A, Bayer AS. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother,2013,57(11):5658-64. doi: 10.1128/AAC.01184-13..
[29] Chen CJ, Huang YC, Chiu CH2. Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia. J Antimicrob Chemother,2015,70(11):2965-72. doi: 10.1093/jac/dkv225.
[30] Troxler R, von Graevenitz A, Funke G, Wiedemann B, Stock I. Natural antibiotic susceptibility of Listeria species: L. grayi, L. innocua, L. ivanovii, L. monocytogenes, L. seeligeri and L. welshimeri strains. Clin Microbiol Infect,2000,6(10):525-35. doi: 10.1046/j.1469-0691.2000.00168.x.
[31] Scortti M, Han L, Alvarez S, Leclercq A, Moura A, Lecuit M, Vazquez-Boland J. Epistatic control of intrinsic resistance by virulence genes in Listeria. PLoS Genet,2018,14(9):e1007525. doi: 10.1371/journal.pgen.1007525.
[32] Phelps CC, Vadia S, Arnett E, Tan Y, Zhang X, Pathak-Sharma S, Gavrilin MA, Seveau S. Relative Roles of Listeriolysin O, InlA, and InlB in Listeria monocytogenes Uptake by Host Cells. Infect Immun,2018,86(10). pii: e00555-18. doi: 10.1128/IAI.00555-18.
[33] Gründler T, Quednau N, Stump C, Orian-Rousseau V, Ishikawa H, Wolburg H, Schroten H, Tenenbaum T, Schwerk C. The surface proteins InlA and InlB are interdependently required for polar basolateral invasion by Listeria monocytogenes in a human model of the blood-cerebrospinal fluid barrier. Microbes Infect,2013,15(4):291-301. doi: 10.1016/j.micinf.2012.12.005.
[34] Gessain G, Tsai YH, Travier L, Bonazzi M, Grayo S, Cossart P, Charlier C, Disson O, Lecuit M. PI3-kinase activation is critical for host barrier permissiveness to Listeria monocytogenes. J Exp Med,2015,212(2):165-83. doi: 10.1084/jem.20141406.
[35] Camejo A, Carvalho F, Reis O, Leitão E, Sousa S, Cabanes D. The arsenal of virulence factors deployed by Listeria monocytogenes to promote its cell infection cycle. Virulence,2011, 2(5):379-94. doi: 10.4161/viru.2.5.17703.
[36] Yin Y, Yao H, Doijad S, Kong S, Shen Y, Cai X, Tan W, Wang Y, Feng Y, Ling Z, Wang G, Hu Y, Lian K, Sun X, Liu Y, Wang C, Jiao K, Liu G, Song R, Chen X, Pan Z, Loessner MJ, Chakraborty T, Jiao X. A hybrid sub-lineage of Listeria monocytogenes comprising hypervirulent isolates. Nat Commun,2019 Sep 30;10(1):4283. doi: 10.1038/s41467-019-12072-1.
[37] Tamburro M, Sammarco ML, Ammendolia MG, Fanelli I, Minelli F, Ripabelli G. Evaluation of transcription levels of inlA, inlB, hly, bsh and prfA genes in Listeria monocytogenes strains using quantitative reverse-transcription PCR and ability of invasion into human CaCo-2 cells. FEMS Microbiol Lett,2015,362(6). pii: fnv018. doi: 10.1093/femsle/fnv018.
[38] Appleman MD, Cherubin CE, Heseltine PNR, Stratton CW. Susceptibility testing of Listeria monocytogenes. A reassessment of bactericidal activity as a predictor for clinical outcome. Diagn Microbiol Infect Dis,1991,14(4):311-7. doi: 10.1016/0732-8893(91)90022-8.
[39] Stepanović S, Lazarević G, Jesić M, Kos R. Meropenem therapy failure in Listeria monocytogenes infection. Eur J Clin Microbiol Infect Dis,2004,23(6):484-6. doi: 10.1007/s10096-004-1135-3.
[40] Thønnings S, Knudsen JD, Schønheyder HC, Søgaard M, Arpi M, Gradel KO, Østergaard C; Danish Collaborative Bacteraemia Network (DACOBAN). Antibiotic treatment and mortality in patients with Listeria monocytogenes meningitis or bacteraemia. Clin Microbiol Infect,2016,22(8):725-30. doi: 10.1016/j.cmi.2016.06.006.
[41] Blatt SP, Zajac RA. Treatment of Listeria bacteremia with vancomycin. Rev Infect Dis,1991,13(1):181-2. doi: 10.1093/clinids/12.5.181.
[42] Bonacorsi S, Doit C, Aujard Y, Blot P, Bingen E. Successful antepartum treatment of listeriosis with vancomycin plus netilmicin. Clin Infect Dis,1993,17(1):139-40. doi: 10.1093/clinids/17.1.139.
[43] Baldassarre JS, Ingerman MJ, Nansteel J, Santoro J. Development of Listeria meningitis during vancomycin therapy: a case report. J Infect Dis,1991,164(1):221-2. doi: 10.1093/infdis/164.1.221.
[44] Grant MH, Ravreby H, Lorber B. Cure of Listeria monocytogenes meningitis after early transition to oral therapy. Antimicrob Agents Chemother,2010,54(5):2276-7. doi: 10.1128/AAC.01815-09.